Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04571840 · ClinicalTrials.gov registry record · NA

Prostate Imaging Using MRI +/- Contrast Enhancement

A NA study of Prostate Cancer, sponsored by University College, London.

Active
Registry status
NA
Development phase
500
Enrollment target
20
Study locations

NCT04571840 is a NA study of Prostate Cancer that is active but no longer recruiting, run by University College, London. The registered enrollment target is 500 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04571840, a NA study of Prostate Cancer, is active but no longer recruiting, sponsored by University College, London.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that requires injection of IV contrast (the current standard practice) versus MRI scans that can be performed without IV contrast in the detection of prostate cancer.

Conditions Studied

Prostate Cancer

Interventions

  • DIAGNOSTIC_TEST Multiparametric MRI +/- prostate biopsy
  • DIAGNOSTIC_TEST Biparametric MRI +/- prostate biopsy

Study Locations (20)

Other

  • Centro de Urologia - Buenos Aires
  • Monash University - Melbourne
  • Peter MacCallum Cancer Centre - Melbourne E.
  • Ghent University Hospital - Ghent
  • Hospital Sírio-Libanês - São Paulo
  • Princess Margaret Cancer Centre - Toronto
  • Herlev and Gentofte Hospital - Copenhagen
  • Helsinki University Hospital - Helsinki
  • Bordeaux Pellegrin University Hospital - Bordeaux
  • CHU Lille - Lille
  • Sorbonne Université - Paris
  • Heinrich Heine University Düsseldorf - Düsseldorf
  • Essen University Hospital - Essen
  • University Hospital Frankfurt - Frankfurt
  • Martini Klinik - Hamburg
  • San Raffaele Hospital - Milan

New York

  • NYU Langone - New York
  • Icahn School of Medicine (Mount Sinai) - New York
  • New York Presbyterian Hospital - New York

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2022-03-22
Est. Completion 2025-03-01
Phase NA

Sponsor

University College, London

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04571840

The ClinicalTrials.gov registry entry for NCT04571840 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (18% lower). The listed sponsor is University College, London, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Multiparametric MRI +/- prostate biopsy is the first listed.

NCT04571840 reports 20 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04571840 about?

NCT04571840 is a clinical study titled "Prostate Imaging Using MRI +/- Contrast Enhancement". This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. This means that we are comparing MRI scans that ...

What is the current status of trial NCT04571840?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2022-03-22. Estimated completion is 2025-03-01.

What conditions does trial NCT04571840 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT04571840?

The interventions under investigation include: Multiparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST), Biparametric MRI +/- prostate biopsy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT04571840?

This trial is sponsored by University College, London, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04571840 being conducted?

This trial has 20 study locations across Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.